Physician profile
Jacquelyn Means
NPI 1134487259
$2,109.25
in general payments reported to CMS, 2019-2025
31 companies · $421 in 2025
The $421 reported for 2025 was more than what 76% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $391 · 2020: $102 · 2021: $119 · 2022: $260 · 2023: $297 · 2024: $520 · 2025: $421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,237.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $273.53 | 2019-2024 | |
| Organon LLC | $243.90 | 2021-2025 | Nexplanon |
| Abbvie INC. | $237.38 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $200.71 | 2023-2025 | Myfembree |
| Astellas Pharma US INC | $161.90 | 2024-2025 | Veozah |
| Sage Therapeutics, LLC | $94.44 | 2024-2025 | Zurzuvae |
| Smith+Nephew, INC. | $82.63 | 2019-2021 | |
| Exeltis, USA INC. | $79.91 | 2024-2025 | Slynd |
| Millicent US INC | $69.03 | 2020-2025 | Femlyv, Femring, Intrarosa |
| Therapeuticsmd, INC. | $66.96 | 2019-2021 | |
| Lupin INC. | $54.30 | 2019-2020 | |
| Innovation Technologies INC | $48.21 | 2023 | Irrisept |
| Minerva Surgical, INC | $46.62 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $45.38 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $44.53 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $43.99 | 2019-2024 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $42.11 | 2022-2025 | |
| Axonics, INC. | $33.79 | 2024 | Axonics |
| Duchesnay USA Incorporated | $29.60 | 2019 | |
| Novo Nordisk INC | $28.09 | 2019-2020 | |
| Vertex Pharmaceuticals Incorporated | $23.50 | 2025 | |
| Amgen INC. | $21.30 | 2025 | Evenity, Prolia |
| Pacira Pharmaceuticals Incorporated | $20.53 | 2019 | |
| Baxter Healthcare | $19.72 | 2021 | |
| Coopersurgical, INC. | $17.63 | 2025 | |
| Lilly USA, LLC | $17.03 | 2024 | Zepbound, Jardiance |
| Mission Pharmacal Company | $14.38 | 2020 | |
| Idorsia Pharmaceuticals US INC | $13.31 | 2024 | Quviviq |
| Coloplast Corp | $12.89 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $11.21 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacquelyn Means listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.